SELF-ADMINISTERED V. PROVIDER ADMINISTERED: How route of administration in oncology products affects payer coverage and product strategy

Pharmaceutical manufacturers have deployed manufacturing techniques to create self-administered oncology products. As a result, they are changing the treatment paradigm-from one where patients receive treatment in the physician office or healthcare organization setting to one where patients can receive therapies nearly anywhere. This increase in patient convenience comes at a premium price, though, and insurers have taken notice. Public and private payers are rapidly and substantially adapting their coverage policies to manage utilization and control costs. Given the changing oncology landscape, stakeholders in the oncology market seek solid analysis to understand the true impact route of administration has on product success, reimbursement and patient access.

New research from Xcenda provides answers to strategic questions facing the oncology market:

• How has drug coverage evolved in the public and private payer markets?
• How is reimbursement for self-administered and injectable oncology agents distinguished in the marketplace?
• Are the economic incentives properly aligned to insure access and payment for product and services?
• What are the key issues and concerns for providers, payers and patients?
• How are managed care organizations evaluating oncology agents for formulary consideration?
• How do coverage policies influence treatment preferences of oncologists?
   

Report Scope
This report uses data from historical, primary and secondary sources to explore critical issues related to self-administered and provider-administered oncology products. Key report features include:

• Contrasted stakeholder perspectives: payer, provider and patients
• Unique data sets from AmerisourceBergen Specialty Group, including primary market research with commercial medical and pharmacy directors (representing more than 100 million lives - via Xcenda's Managed Care Network) and prescribing oncologists (via NMCR Analytics)
• Oncology specialties: breast, lung and renal cancers
• Supplemental secondary research focusing on:
  - Evolution of drug coverage for oncology agents in the public and private payer markets
  - Trends in utilization, cost, formulary status and out-of-pocket requirements
   

Developed by Xcenda in conjunction with sister company NMCR Analytics, this crucial research is now available at http://syndicatedreports.xcendaprojects.com.

info@xcenda.com or 800-320-6497